Seven-tesla proton magnetic resonance spectroscopic imaging in adult X-linked adrenoleukodystrophy

Archives of Neurology

Volumn 65, Issue 11, 2008, Pages 1488-1494

  Ratai, Eva ^a,b   Kok, Trina ^c   Wiggins, Christopher ^a,b   Wiggins, Graham ^a,b   Grant, Ellen ^a,b   Gagoski, Borjan ^c   O'Neill, Gilmore ^a,b   Adalsteinsson, Elfar ^c,d   Eichler, Florian ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c USA   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATINE; GLUTAMIC ACID; INOSITOL; N ACETYLASPARTIC ACID;

ADRENOLEUKODYSTROPHY; ADULT; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HETEROZYGOTE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYMPTOM; WHITE MATTER; X CHROMOSOME LINKED DISORDER;

ADRENOLEUKODYSTROPHY; ADULT; AGED; BRAIN; CHOLINE; CREATINE; DISABILITY EVALUATION; FATTY ACIDS; FEMALE; HETEROZYGOTE; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PERIAQUEDUCTAL GRAY; PHENOTYPE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; YOUNG ADULT;

EID: 55949109698     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.11.1488     Document Type: Article

References (26)

1. Moser H, Smith K, Watkins P, et al. X-linked adrenoleukodystrophy. In: Scriver C, Sly WS, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw Hill; 2001:3257-3301.
2. Moser HW, Loes DJ, Melhem ER, et al. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality, a study involving 372 patients. Neuropediatrics. 2000;31(5):227-239.
3. van Geel BM, Assies J, Haverkort EB, et al. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil." J Neurol Neurosurg Psychiatry. 1999;67(3):290-299.
4. van Geel BM, Bezman L, Loes DJ, et al. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol. 2001;49(2):186-194.
5. Fatemi A, Barker PB, Ulug AM, et al. MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy. Neurology. 2003;60(8):1301-1307.
6. Moser AB, Kreiter N, Bezman L, et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol. 1999;45(1):100-110.
7. Eichler F, Mahmood A, Loes D, et al. Magnetic resonance imaging detection of lesion progression in adult patients with X-linked adrenoleukodystrophy. Arch Neurol. 2007;64(5):659-664.
8. Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev. 1989;13(1):23-31.
9. Barker PB, Breiter SN, Soher BJ, et al. Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn Reson Med. 1994;32(2):157-163.
10. Pouwels PJ, Kruse B, Korenke GC, et al. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics. 1998;29(5):254-264.
11. Tzika AA, Ball WS, Vigneron DB, et al. Childhood adrenoleukodystrophy: assessment with proton MR spectroscopy. Radiology. 1993;189(2):467-480.
12. Wiggins GC, Potthast A, Triantafyllou C, et al. Eight-channel phased array coil and detunable TEM volume coil for 7 T brain imaging. Magn Reson Med. 2005;54(1):235-240.
13. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001;14(4):260-264.
14. Ross BD, Bluml S, Cowan R, et al. In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am. 1998;8(4):809-822.
15. Broom KA, Anthony DC, Lowe JP, et al. MRI and MRS alterations in the preclinical phase of murine prion disease: association with neuropathological and behavioural changes. Neurobiol Dis. 2007;26(3):707-717.
16. Fouquet F, Zhou JM, Ralston E, et al. Expression of the adrenoleukodystrophy protein in the human and mouse central nervous system. Neurobiol Dis. 1997;3(4):271-285.
17. Dubey P, Fatemi A, Barker PB, et al. Spectroscopic evidence of cerebral axonopathy in patients with "pure" adrenomyeloneuropathy. Neurology. 2005;64(2):304-310.
18. Kassmann CM, Lappe-Siefke C, Baes M, et al. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet. 2007;39(8):969-976.
19. Aubourg P. Axons need glial peroxisomes. Nat Genet. 2007;39(8):936-938.
20. Hattori N, Abe K, Sakoda S, et al. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport. 2002;13(1):183-186.
21. Antuono PG, Jones JL, Wang Y, et al. Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T. Neurology. 2001;56(6):737-742.
22. Schaumburg HH, Powers JM, Raine CS, et al. Adrenoleukodystrophy: a clinical and pathological study of 17 cases. Arch Neurol. 1975;32(9):577-591.
23. Garside S, Rosebush PI, Levinson AJ, et al. Late-onset adrenoleukodystrophy associated with long-standing psychiatric symptoms. J Clin Psychiatry. 1999;60(7):460-468.
24. Rosebush PI, Garside S, Levinson AJ, et al. The neuropsychiatry of adult-onset adrenoleukodystrophy. J Neuropsychiatry Clin Neurosci. 1999;11(3):315-327.
25. Adalsteinsson E, Irarrazabal P, Topp S, et al. Volumetric spectroscopic imaging with spiral-based k-space trajectories. Magn Reson Med. 1998;39(6):889-898.
26. Kim DH, Adalsteinsson E, Spielman DM. Spiral readout gradients for the reduction of motion artifacts in chemical shift imaging. Magn Reson Med. 2004;51(3):458-463.